Nature Communications (Jul 2021)
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
- Cecile Geuijen,
- Paul Tacken,
- Liang-Chuan Wang,
- Rinse Klooster,
- Pieter Fokko van Loo,
- Jing Zhou,
- Arpita Mondal,
- Yao-bin Liu,
- Arjen Kramer,
- Thomas Condamine,
- Alla Volgina,
- Linda J. A. Hendriks,
- Hans van der Maaden,
- Eric Rovers,
- Steef Engels,
- Floris Fransen,
- Renate den Blanken-Smit,
- Vanessa Zondag-van der Zande,
- Abdul Basmeleh,
- Willem Bartelink,
- Ashwini Kulkarni,
- Wilfred Marissen,
- Cheng-Yen Huang,
- Leslie Hall,
- Shane Harvey,
- Soyeon Kim,
- Marina Martinez,
- Shaun O’Brien,
- Edmund Moon,
- Steven Albelda,
- Chrysi Kanellopoulou,
- Shaun Stewart,
- Horacio Nastri,
- Alexander B. H. Bakker,
- Peggy Scherle,
- Ton Logtenberg,
- Gregory Hollis,
- John de Kruif,
- Reid Huber,
- Patrick A. Mayes,
- Mark Throsby
Affiliations
- Cecile Geuijen
- Merus NV
- Paul Tacken
- Merus NV
- Liang-Chuan Wang
- Incyte Corporation
- Rinse Klooster
- Merus NV
- Pieter Fokko van Loo
- Merus NV
- Jing Zhou
- Incyte Corporation
- Arpita Mondal
- Incyte Corporation
- Yao-bin Liu
- Incyte Corporation
- Arjen Kramer
- Merus NV
- Thomas Condamine
- Incyte Corporation
- Alla Volgina
- Incyte Corporation
- Linda J. A. Hendriks
- Merus NV
- Hans van der Maaden
- Merus NV
- Eric Rovers
- Merus NV
- Steef Engels
- Merus NV
- Floris Fransen
- Merus NV
- Renate den Blanken-Smit
- Merus NV
- Vanessa Zondag-van der Zande
- Merus NV
- Abdul Basmeleh
- Merus NV
- Willem Bartelink
- Merus NV
- Ashwini Kulkarni
- Incyte Corporation
- Wilfred Marissen
- Merus NV
- Cheng-Yen Huang
- Incyte Corporation
- Leslie Hall
- Incyte Corporation
- Shane Harvey
- Incyte Corporation
- Soyeon Kim
- Perelman School of Medicine, University of Pennsylvania
- Marina Martinez
- Perelman School of Medicine, University of Pennsylvania
- Shaun O’Brien
- Perelman School of Medicine, University of Pennsylvania
- Edmund Moon
- Perelman School of Medicine, University of Pennsylvania
- Steven Albelda
- Perelman School of Medicine, University of Pennsylvania
- Chrysi Kanellopoulou
- Incyte Corporation
- Shaun Stewart
- Incyte Corporation
- Horacio Nastri
- Incyte Corporation
- Alexander B. H. Bakker
- Merus NV
- Peggy Scherle
- Incyte Corporation
- Ton Logtenberg
- Merus NV
- Gregory Hollis
- Incyte Corporation
- John de Kruif
- Merus NV
- Reid Huber
- Incyte Corporation
- Patrick A. Mayes
- Incyte Corporation
- Mark Throsby
- Merus NV
- DOI
- https://doi.org/10.1038/s41467-021-24767-5
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 19
Abstract
The anti-tumour effect of immune checkpoint inhibitors is potentiated by CD137 agonists in preclinical models, but translation of these results to the clinical practice is hampered by toxicity. Authors describe here a human CD137xPD-L1 bispecific antibody with improved anti-cancer activity whilst maintaining low toxicity in non-human primates.
